Announcement
20.03.2013
At the company's Annual General Meeting today, the following decisions were taken:
- The NeuroSearch Annual Report 2012 was adopted
-
The Board of Director’s proposal regarding the transfer of profits and losses for 2012 to next year was adopted
- The Board of Directors was re-elected and thus still consists of Allan Andersen (Chairman), Torbjörn Bjerke and Christian Lundgren as well as the employee representatives Lars Siim Madsen and Morten Henrik Nielsen
-
PricewaterhouseCoopers was re-elected as the company's auditor
- The general meeting authorised the Board to purchase own shares of up to a total nominal value of DKK 2,455,394 (corresponding to 10% of the company's present share capital) in the period until the next Annual General Meeting
- The proposed fee to the Board of Directors for 2013 was adopted.
|
Allan Andersen Chairman of the Board of Directors |
René Schneider CEO |
Contact person
René Schneider, CEO, telephone: +45 2911 2097
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.
